Literature DB >> 25223996

Variability in telavancin cross-reactivity among vancomycin immunoassays.

Kevin W McConeghy1, Siyun Liao1, Douglas Clark2, Philip Worboys3, Steven L Barriere2, Keith A Rodvold4.   

Abstract

Telavancin is a semisynthetic lipoglycopeptide with a dual mechanism of action against Gram-positive pathogens. Two brief reports have suggested potential cross-reactivity of telavancin with the vancomycin particle-enhanced turbidometric immunoassay (PETIA). The purpose of this study was to evaluate several commercially available vancomycin immunoassays (fluorescence polarization [FPIA], enzyme-multiplied immunoassays [EMIT], PETIA, and chemiluminescent immunoassay [CMIA]) for cross-reactivity with telavancin. Seven sites were selected to analyze serum samples for vancomycin. Each site received a set of samples (n = 18) which combined drug-free serum with telavancin, 7-OH telavancin metabolite, or vancomycin. Immunoassays demonstrating potential cross-reactivity were further evaluated by sending a duplicate sample set to multiple laboratories. Cross-reactivity was defined as the percent theoretical concentration (reported concentration/theoretical concentration × 100). No cross-reactivity was seen with FPIA or EMIT. Within the theoretical concentration range of 5 to 120 μg/ml of telavancin, the Synchron PETIA system reported vancomycin concentrations ranging from 4.7 to 54.2 μg/ml compared to vancomycin concentrations from 1.1 to 5.6 μg/ml for the Vista PETIA system. The Architect CMIA system reported vancomycin concentrations in the range of 0.27 to 0.97 μg/ml, whereas Advia Centaur XP CMIA reported vancomycin concentrations between 1.6 and 31.6 μg/ml. The Architect CMIA immunoassay had the lowest percent cross-reactivity (0.8 to 5.4%), while the Synchron PETIA immunoassay demonstrated the highest percent cross-reactivity (45.2 to 53.8%). Telavancin samples measured by liquid chromatography-mass spectroscopy were within 93.9 to 122% of theoretical concentrations. Vancomycin concentrations were not measured in any 7-OH telavancin-spiked sample. Vancomycin concentrations measured by liquid chromatography-mass spectroscopy were within 57.2 to 113% of theoretical concentrations. PETIA and CMIA measured vancomycin concentrations in telavancin-spiked samples. Significant variability in percent cross-reactivity was observed for each platform regardless of immunoassay method.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25223996      PMCID: PMC4249549          DOI: 10.1128/AAC.03785-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

Review 1.  Implications of vancomycin degradation products on therapeutic drug monitoring in patients with end-stage renal disease.

Authors:  A L Somerville; D H Wright; J C Rotschafer
Journal:  Pharmacotherapy       Date:  1999-06       Impact factor: 4.705

2.  Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424).

Authors:  Michael R Leadbetter; Stacy M Adams; Bettina Bazzini; Paul R Fatheree; Dane E Karr; Kevin M Krause; Bernice M T Lam; Martin S Linsell; Matthew B Nodwell; John L Pace; Kelly Quast; Jeng-Pyng Shaw; Elizabeth Soriano; Sean G Trapp; Jenny D Villena; Terry X Wu; Burton G Christensen; J Kevin Judice
Journal:  J Antibiot (Tokyo)       Date:  2004-05       Impact factor: 2.649

3.  Detection of vancomycin levels in patients receiving telavancin but not vancomycin.

Authors:  Michael S Gelfand; Kerry O Cleveland; Kashif A Memon
Journal:  J Antimicrob Chemother       Date:  2011-10-20       Impact factor: 5.790

4.  Can a vancomycin assay be utilised to predict plasma telavancin concentrations?

Authors:  Derek J Evans; Rita M Windisch; Henry R Freedy; Hector F Bonilla
Journal:  Int J Antimicrob Agents       Date:  2013-03-21       Impact factor: 5.283

5.  Mass balance and pharmacokinetics of [14C]telavancin following intravenous administration to healthy male volunteers.

Authors:  Jeng-Pyng Shaw; Jonathan Cheong; Michael R Goldberg; Michael M Kitt
Journal:  Antimicrob Agents Chemother       Date:  2010-06-01       Impact factor: 5.191

6.  Telavancin pharmacokinetics and pharmacodynamics in patients with complicated skin and skin structure infections and various degrees of renal function.

Authors:  T P Lodise; J M Butterfield; S S Hegde; E Samara; S L Barriere
Journal:  Antimicrob Agents Chemother       Date:  2012-01-17       Impact factor: 5.191

7.  Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.

Authors:  Mark H Gotfried; Jeng-Pyng Shaw; Bret M Benton; Kevin M Krause; Michael R Goldberg; Michael M Kitt; Steven L Barriere
Journal:  Antimicrob Agents Chemother       Date:  2007-10-08       Impact factor: 5.191

  7 in total
  1 in total

Review 1.  Pharmacokinetic drug evaluation of tedizolid for the treatment of skin infections.

Authors:  Darrell McBride; Tamara Krekel; Kevin Hsueh; Michael J Durkin
Journal:  Expert Opin Drug Metab Toxicol       Date:  2017-02-16       Impact factor: 4.481

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.